Abstract: Sudden cardiac death (SCD) from cardiac arrest is a major international public health problem accounting for an estimated 15%–20% of all deaths. Although resuscitation rates are generally improving throughout the world, the majority of individuals who experience a sudden cardiac arrest will not survive. SCD most often develops in older adults with acquired structural heart disease, but it also rarely occurs in the young, where it is more commonly because of inherited disorders. Coronary heart disease is known to be the most common pathology underlying SCD, followed by cardiomyopathies, inherited arrhythmia syndromes, and valvular heart disease. During the past 3 decades, declines in SCD rates have not been as steep as for other causes of coronary heart disease deaths, and there is a growing fraction of SCDs not due to coronary heart disease and ventricular arrhythmias, particularly among certain subsets of the population. The growing heterogeneity of the pathologies and mechanisms underlying SCD present major challenges for SCD prevention, which are magnified further by a frequent lack of recognition of the underlying cardiac condition before death. Multifaceted preventative approaches, which address risk factors in seemingly low-risk and known high-risk populations, will be required to decrease the burden of SCD. In this Compendium, we review the wide-ranging spectrum of epidemiology underlying SCD within both the general population and high-risk subsets with established cardiac disease placing an emphasis on recent global trends, remaining uncertainties, and potential targeted preventive strategies.

Key Words: cardiomyopathies ■ coronary disease ■ death, sudden, cardiac ■ epidemiology
Sudden Cardiac Death/Sudden Cardiac Arrest: Background, Mechanisms, and Risks

Sudden cardiac death (SCD)/sudden cardiac arrest (SCA) refers to an unexpected death or arrest from a cardiovascular cause that occurs rapidly outside of the hospital or in the emergency room. The presumption based on epidemiologic studies of SCD and SCA survivors is that such rapid deaths are often because of lethal ventricular arrhythmias in the setting of underlying coronary heart disease (CHD). Despite major advances in treatment and prevention of CHD and implantable cardioverter defibrillators (ICDs) for SCD prevention in high-risk patients, SCD remains a major public health problem because of lethal ventricular arrhythmias in the setting of underlying coronary heart disease (CHD).3–5 Despite major advances in treatment and prevention of CHD and implantable cardioverter defibrillators (ICDs) for SCD prevention in high-risk patients, SCD remains a major public health problem estimated to account for 15%–20% of all deaths.6,7 Reported high-risk patients, SCD remains a major public health problem.

SCA Incidence: Estimates and Definitions

Estimates on the annual incidence of SCA and SCD vary widely depending on data sources for case ascertainment, definitions used, and methods used for extrapolation of rates. These difficulties in extrapolating SCA and SCD rates are likely magnified further when comparing SCD rates across countries where emergency medical service (EMS) protocols, autopsy rates, and national recording systems vary. The majority of global comparisons (Figure 1) are based on rates of EMS-attended out of hospital cardiac arrests (OHCA), which seem to be much lower in Asia (52.5 per 100,000 person-years) as compared with Europe (86.4 per 100,000 person-years), North America (98.1 per 100,000 person-years), and Australia (111.9 per 100,000 person-years). There also seem to be regional variations within geographic regions. For instance, among 10 regions in North America, rates of EMS attended cardiac arrest range from 159 per 100,000 person-years in Dallas, TX, to 71.8 per 100,000 person-years in Ottawa, ON.

However, the above estimates are crude approximations which at the same time both over- and under-estimate SCA rates. First, EMS is not in attendance for a significant fraction of SCAs, and the proportion of EMS-attended deaths is known to vary significantly across countries. Second, a significant fraction of EMS-attended OHCA are not unexpected nor do they occur in a short time frame from the onset of symptoms. Death certificates are also known to overestimate SCD rates for similar reasons. To obtain a more precise estimate of SCD/SCA, expert panels have advocated for the establishment of precise and uniform definitions of SCD/SCA and to integrate multiple source methods for case ascertainment. Standardized definitions of SCD/SCA have been particularly among certain subsets of the population. In addition, SCD preventive strategies are lacking in low-risk individuals without established heart disease that comprise the largest proportion of SCDs. To further reduce the incidence of SCD, preventive strategies need to be tailored to diverse populations at varying levels of risk. In this Compendium, we review the broad spectrum of epidemiology underlying SCD, from common to rare forms, with an emphasis on preventive strategies, recent trends, and unanswered questions.

**Nonstandard Abbreviations and Acronyms**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AF</td>
<td>atrial fibrillation</td>
</tr>
<tr>
<td>ARVC</td>
<td>arrhythmogenic right ventricular cardiomyopathy</td>
</tr>
<tr>
<td>BrS</td>
<td>Brugada syndrome</td>
</tr>
<tr>
<td>CHD</td>
<td>coronary heart disease</td>
</tr>
<tr>
<td>EMS</td>
<td>emergency medical service</td>
</tr>
<tr>
<td>ERP</td>
<td>early repolarization ECG pattern</td>
</tr>
<tr>
<td>HCM</td>
<td>hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>HF</td>
<td>heart failure</td>
</tr>
<tr>
<td>ICD</td>
<td>implantable cardioverter defibrillator</td>
</tr>
<tr>
<td>LQTS</td>
<td>long-QT syndrome</td>
</tr>
<tr>
<td>LVEF</td>
<td>left ventricular ejection fraction</td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction</td>
</tr>
<tr>
<td>NIDCM</td>
<td>non–ischemic dilated cardiomyopathy</td>
</tr>
<tr>
<td>OHCA</td>
<td>out of hospital cardiac arrests</td>
</tr>
<tr>
<td>PEA</td>
<td>pulseless electrical activity</td>
</tr>
<tr>
<td>SCA</td>
<td>sudden cardiac arrest</td>
</tr>
<tr>
<td>SCD</td>
<td>sudden cardiac death</td>
</tr>
<tr>
<td>VF</td>
<td>ventricular fibrillation</td>
</tr>
<tr>
<td>VT</td>
<td>ventricular tachycardia</td>
</tr>
</tbody>
</table>

*Figure 1. Incidence rates of emergency medical service (EMS)-attended out of hospital cardiac arrests (OHCA; A), EMS-treated OHCA (B), and EMS-treated OHCA of presumed cardiac cause (C). Incidence is per 100,000 person-years. Compared with Europe, North America, and Australia, EMS-attended OHCA was lower in Asia, and EMS-treated OHCA of presumed cardiac cause was higher in North America than in other regions. *P<0.05; **P<0.01; and ***P<0.001. Adapted from Berdowski et al17 with permission of the publisher. Copyright © 2010, Elsevier. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.*
proposed, which generally define SCD as an unexpected death without obvious extra-cardiac cause that occurs in association with a witnessed rapid collapse or within 1 hour of the onset of symptoms. There are no national surveillance mechanisms to record such characteristics of deaths; and therefore, approximations are based on extrapolations from population-based studies. In prospective studies using standardized definitions and multiple sources of surveillance for case ascertainment in the United States, Netherlands, Ireland, and China, SCAD rates range from 40 to 100 per 100,000 in the general population, with rates being lowest in China. In individuals aged <35 years, SCAD is rare with an incidence of 1 to 3 per 100,000 per year in recent reports.

Even when a strict definition and multiple sources of ascertainment are used, other noncardiac conditions that evolve rapidly such as acute cerebral hemorrhage, aortic rupture, and pulmonary embolism cannot be excluded without a carefully performed autopsy. Autopsy rates are generally low and vary widely across countries with rates as low as 10% of all deaths within the United States compared with 23.8% in Finland, and the protocols for the performance of autopsies in the cases of suspected SCAD vary widely as well, even within regions of countries. These differences in autopsy rates and protocols likely contribute to some of the geographical differences in the incidence and causes of SCAD.

SCA Trends in Survival and Underlying Rhythm

Several major advances in cardiopulmonary resuscitation (CPR) and postresuscitation care have resulted in improved resuscitation rates from OHCA. In a recent report from the Cardiac Arrest Registry to Enhance Survival, a prospective clinical registry of 70,000 OHCA survivors in the United States, survival rates to hospital discharge increased from 5.7% in 2005 to 8.3% in 2012. In Denmark, even greater increases in 30-day survival (3.5%–10.8%) were observed from 2001 to 2010. Both inhospital and prehospital survival rates contribute to these improved outcomes post OHCA. However, even with these improvements, absolute survival rates remain in the ≤10% range.

Although survival rates are higher for OHCA where ventricular fibrillation (VF) is the initial rhythm (21%), the proportion of cases where VF is found at the time of EMS arrival has been declining during the past 3 decades, with a resultant increase in cases where pulseless electrical activity (PEA) and asystole are the initial rhythm. This is an unsettling trend because resuscitation rates are much lower for these rhythms, and we currently have no known strategies for prevention of these deaths. Part of this changing pattern seems to be explained by a concomitant increase in the proportion of arrests occurring in the home, where the arrest is less likely to be witnessed. However, even when the arrest is witnessed by a bystander or an automated external defibrillator is applied, VF or pulseless ventricular tachycardia (VT) is less likely to be encountered as the initial rhythm in arrests occurring in the home versus public. Proposed explanations for the proportional decline in VF as compared with other rhythms include an overall decrease in the prevalence of CHD and an increased use of β-blockers and ICDs in high-risk patients. At the same time, the population is aging, and advances in medical treatments have resulted in an increased prevalence of end-stage cardiovascular disease as well as other severe comorbidities. These older, sicker patients may be more likely to have arrests in the home setting and to have acute precipitants leading to PEA (ie, respiratory, metabolic, and vascular) and be less likely to sustain VF up to the point of EMS arrival.

Demographics of SCAD Victims

The majority of SCADs occur in the adult population, with <1% occurring in individuals aged <35 years. Among adults, the absolute rate of SCD increases markedly with age; however, the proportion of deaths that are sudden seems to be higher in younger age groups. There are also recognized differences in SCD incidence by sex and race, which are largely unexplained. Women have a lower incidence of SCD and SCAD than men, even when one accounts for the prevalence of other predisposing conditions such as CHD, myocardial infarction (MI), and heart failure (HF). Women who experience OHCA are on average older, more likely to present with PEA, and experience their arrest at home as compared with men. These demographics may partially explain why the decline in SCD and OHCA rate has been less pronounced among women as opposed to men in recent years. However, women, especially at younger ages, seem to have a higher rate of successful resuscitation and survival from shockable rhythms, possibly because of favorable effects of smaller body size and estrogen on success of defibrillation and postresuscitation hemodynamics.

With respect to race, black as opposed to white Americans have been documented to have higher rates of OHCA and SCAD as well as poorer rates of survival from cardiac arrest. Similar to women, blacks of both sexes are more likely to have an unwitnessed arrest or PEA documented at the time of the arrest. These unfavorable arrest characteristics do not entirely account for the poorer survival among blacks. Even when limited to OHCAs because of VF/VT, national rates of survival to hospital discharge have been documented to be 27% lower among black patients, and much, but not all, of this disparity seems to be explained by black patients receiving treatment at hospitals with worse outcomes. Blacks may also be less likely to receive prehospital resuscitation efforts in the United States. In 1 recent large cohort study, patients with OHCA in low-income black neighborhoods were less likely to receive bystander-initiated CPR than those in high-income white neighborhoods.

Data are even more limited for other racial and ethnic differences in SCD incidence. Despite having a higher prevalence of cardiac risk factors, Hispanic Americans may have lower SCD rates than non-Hispanic populations based on limited data from death certificates and coroner evaluations in the United States. It also seems that the incidence of SCD may be lower among Asian populations in the United States based on death certificate data. Estimates of SCD incidence in longitudinal population-based studies of SCAD in China and Japan are consistently lower than those from studies performed in North America or other regions with predominantly...
white populations. These racial differences in SCD/SCA incidence and survival are poorly understood, and further studies performed in large-scale population-based cohort studies of diverse ethnicity are needed to determine the origin of these disparities.

**Underlying Pathophysiology of SCD**

The epidemiology of SCD is directly related to the pathophysiology that underlies the event. Our knowledge on the predominant pathologies underlying SCD is primarily dependent on autopsy series and cardiac evaluations in cardiac arrest survivors, the detail nature of which may vary significantly among counties. Variation in the meticulous nature of histologic examinations across countries likely influences the reported proportions of pathologic causes of sudden death worldwide. Despite these limitations, it is generally accepted that CHD is the most common cardiac pathology underlying SCD (Figure 2) in adults aged >35 years, particularly among white men where it is responsible for ≈70%–75% of SCDs. In women, the percentage of SCD and SCA because of CHD seems to be lower. In cardiac arrest survivor series and SCD autopsy series, CHD was found in 45%–50% of women versus 80%–90% of men. The percentage of SCDs with underlying CHD also seems to be lower in blacks versus whites (47% versus 63%) and left ventricular hypertrophy is more common among older black than white SCD victims. In Japan, CHD is thought to account for a much lower percentage of SCDs, although the percentage because of CHD seems to be increasing over time.

Beyond CHD, the causes of SCD are heterogeneous and include cardiomyopathies, valvular heart disease, myocarditis, hypertrophy, and primary electrical heart disease accounting for the remainder. (Figure 2). On average, a significant cardiac abnormality is not found after clinical evaluation or on autopsy in 5% of SCA cases. In Asians, the primary ion channelopathies are estimated to be responsible for 10% of SCDs. In young adults and children aged <35 years, CHD accounts for a much smaller proportion of deaths, with hypertrophic cardiomyopathy (HCM), coronary artery anomalies, myocarditis, arrhythmogenic right ventricular cardiomyopathy (ARVC), and primary ion channelopathies accounting for significant proportions.

The presumed mechanism underlying an abrupt, unheralded death in these conditions is electrical instability leading to a lethal arrhythmia triggered by ischemia or other arrhythmogenic stimuli resulting in acute hemodynamic collapse. This hypothesis is difficult to prove as most deaths are not monitored, and those that are monitored comprise a highly selected population. Studies in epidemiologic cohorts of men and women from the 1970s to 1990s suggest that 88% to 91% of deaths that occur within 1 hour of symptom onset are arrhythmic in nature. Because VF degenerates to asystole during the course of several minutes, the majority of SCD victims demonstrate asystole or PEA when first examined by rescue teams. In cases of SCD where there has been a relatively short delay between collapse and the initial determination of rhythm, the proportion of cases with documented ventricular...
tachyarrhythmias increases to 75% to 80%. However, as mentioned previously, VF is less often and PEA is more commonly encountered in recent OHCA series. Therefore, a proportion of SCD is likely because of abrupt hemodynamic collapse in the absence of preceding fatal arrhythmia, and this proportion may be growing in the population.

### Risk Factors and Predisposing Conditions for SCD in the General Population

The presence of overt structural and primary electrical heart disease is associated with major elevations in SCD risk, and separate risk stratification schema exist for the majority of these disorders, which will be discussed in later sections. However, the majority of SCDs occur among individuals without clinically recognized heart disease. Approximately 44%–52% of men and 59%–69% of women who experience SCD will not have had cardiovascular disease diagnosed before the event, and therefore SCD is the first manifestation of heart disease. Although the absolute incidence among individuals without apparent heart disease is low, the majority of SCD events take place in this segment of the population. For this segment of the population, current efforts directed at preventing SCD primarily comprised risk factor and lifestyle modification.

### CHD Risk Factors

As described above, CHD underlies a significant proportion of SCD, thus risk factors for CHD are associated with SCD risk in the population. Hypertension, diabetes mellitus, hypercholesterolemia, obesity, and smoking have all been associated with elevated risks of SCD among men and women in prospective cohort studies. Diabetes mellitus is a particularly strong risk factor for SCD, even in higher risk populations. Hypertension and resultant left ventricular hypertrophy seem to be particularly important markers of SCD risk in blacks, in whom the prevalence of these conditions is greater. Smoking confers marked elevations in SCD risk, especially among women. Importantly, smoking cessation is associated with a prompt reduction in the elevated risk for SCDs (Figure 3), particularly among individuals who have not yet developed overt CHD. Serum cholesterol seems to be more strongly related to SCD at younger ages, and a recent meta-analysis of randomized trials suggests that cholesterol lowering with statins may confer modest benefits on SCD incidence.

### Family History of SCD

Several studies have demonstrated a familial predisposition to SCD and VF. Three separate case–control studies have demonstrated that a history of SCD among a first-degree relative is an independent risk factor for VF or SCD in the setting of an acute MI. In the Paris Prospective Study, parental history of SCD was an independent risk factor for occurrence of SCD (relative risk, 1.80; 95% confidence interval, 1.11–2.88), but was not associated with fatal MI. Conversely, a parental history of fatal MI had no effect on SCD risk. These data in aggregate suggest that genetic or unknown environmental factors responsible for the familial aggregation of SCD or ischemic VF may predispose to fatal arrhythmia as a discrete trait and manifestation of CHD. The consistent associations implicating a family history of arrhythmic death as an independent risk factor for SCD in the general population has led to several studies focused on identifying common genetic variants that predispose to ventricular arrhythmias and SCD in the population.

### Diet

Dietary intake and blood-based measures of selected nutrients have been specifically associated with SCD in epidemiologic studies. In observational studies, consuming fish ≈1 to 2×/wk has been associated with significant 42%–50% reductions in SCD risk, with minimal impact of risk of non–fatal MI. These inverse associations with SCD were more extreme when marine n-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) were estimated as a proportion of fatty acids from the diet or measured directly in blood.
data in relatively healthy observational cohorts are supportive of experimental data suggesting that n-3 fatty acids may have a selective effect on susceptibility to arrhythmias. However, randomized trial data in post-MI populations have not been consistently supportive of this hypothesis.

Magnesium intake has also been related to SCD rates. In the Nurses’ Health Study, the relative risk of SCD was significantly lower among women in the highest quartile of dietary magnesium intake. The inverse association was stronger for plasma magnesium, where each 0.25 mg/dL (1 SD) increment in plasma magnesium was associated with a 41% reduced risk of SCD. A similar inverse association between serum magnesium and SCD was also found in the Atherosclerosis Risk in Communities study. Finally, there are likely additive and interactive effects of these and other nutrients on SCD incidence. Recent data suggest that a Mediterranean-style diet pattern, consisting of higher intake of vegetables, fruits, nuts, whole grains, fish, and low intake of red/processed meat, may also lower SCD risk among women.

**Alcohol Intake**

The relationship between alcohol intake and SCD is complex. Prospective US cohort studies comprised of individuals consuming small-to-moderate amounts of alcohol have found U-shaped associations between recent alcohol intake and SCD with reduced risks at levels of ½ to 1 drink/d and no reduction at ≥2 drinks/d. Heavy levels of alcohol consumption (>5 drinks/d) have also been associated with increased risk for SCD in other populations. In contrast, alcohol intake has an inverse linear association with non–fatal MI. Recently, consuming >1 drink/d was found to be associated with 2-fold elevations in the risk of experiencing VF during acute ST-segment–elevation MI. These data in aggregate suggest that the favorable effects of alcohol on atherosclerosis and thrombosis may be offset by potential proarrhythmic effects at higher levels of intake.

**Atrial Fibrillation, Renal Disease, and OSA**

Recent data have highlighted the potential link between atrial fibrillation (AF) and SCD. In patients with established AF treated with antiagulation, SCD accounts for >20% of all deaths. In recent population-based cohort and case–control studies, patients with AF have on average a 2.5-fold increased risk of SCD or VF as compared with those without AF. The mechanism underlying this elevation in SCD risk is not completely understood, but it does not seem to be entirely dependent on coexisting cardiovascular disease or explained by the use of antiarrhythmic drugs; however, in a population-based study, much of the excess SCD risk associated with AF could be accounted for by coexisting HF.

Patients with severe chronic kidney disease (CKD) are also at higher risk for SCD, with annualized SCD rates approaching 5.5% in patients undergoing dialysis. There are also recent data to suggest that individuals with more moderate levels of CKD have a higher risk for SCD as compared with people with normal kidney function. Presumably, some of this could be because of electrolyte shifts and significant degrees of left ventricular hypertrophy observed in these patients. Recent data also suggest that obstructive sleep apnea may be contributors to SCD risk in the population. Whether treatment for the above disorders will attenuate the elevated SCD risk is unknown and requires further exploration.

**Triggers of SCD**

**Diurnal/Seasonal Variation**

SCD tends to occur more frequently at certain times of the day, week, and year. SCD incidence peaks from 6:00 AM to noon and is highest on Monday and lowest during the weekend. These morning and Monday peaks in SCD rates seem to be blunted by β-blockers, suggesting that adrenergic triggers may underlie part of these circadian variations. There also seems to be seasonal variability in SCD incidence, with the highest and lowest rates observed in the winter and summer months, respectively, in both hemispheres. These relationships observed in the general population may differ in patients with underlying heart diseases. In patients with ARVC and Brugada syndrome (BrS), ventricular arrhythmias tend to peak in the summer months. These findings suggest that the onset of SCD may be associated with endogenous rhythms and external factors such as activity levels, psychological exposures, sunlight, temperature, and other climatic conditions.

**Physical Activity**

Most studies, but not all, have found protective associations between regular physical activity and SCD or cardiac arrest, particularly for moderate levels of exertion. It is also well recognized that SCD occurs with a higher than average frequency during or shortly after vigorous exertion. The proportion of exertion-related SCDs varies widely from 3% to 13% depending on the population surveyed. Case–control and case–crossover analyses have demonstrated that vigorous exertion can trigger cardiac arrest and SCD, and this risk seems to be greater in men versus women. Habitual exercise lowers this transient excess risk of SCD; however, the risk remains significantly elevated even among those who exercise most frequently.

Despite these risks, the absolute risk of exertion-related SCD is low. Recent population-based estimates on the frequency of exercise-related OHCA and SCD range from 2.1 per 100000 person-years in the Netherlands to 0.46 per 100000 person-years in France. The majority of these exertion-related SCD events took place in adults aged >35 years (Figure 4), and the incidence was 15- to 20-fold higher in men than in women. Even among athletes participating in the same sporting activity, rates of exertion-related SCD remain significantly higher among men.

**Psychosocial Determinants**

Depression, anxiety, and psychological stress have all been linked to SCD and OHCA risk in diverse populations. Anxiety, particularly phobic anxiety, has been directly associated with SCD, but not nonfatal MI, in men and women. Depression and other major psychiatric disorders, in particular schizophrenia, have been associated with higher rates of SCD as well. Potential proarrhythmic properties of...
antipsychotic or antidepressant medications could underlie part of this apparent excess SCD risk observed in patients with psychiatric disorders. In addition to the chronic effects of psychosocial stress, acute mental stress may act as a trigger for SCD.

Acute increases in the incidence of SCD have been documented in populations experiencing disasters such as earthquakes or wars. On the day of the Northridge earthquake, there was a sharp increase in the number of SCDs related to CHD, which was followed by an unusually low incidence of CHD deaths in the week after the earthquake. In contrast, in the recent Japan earthquake and tsunami, where multiple aftershocks occurred and the level of devastation was high in comparison, the incidence of SCD and OHCA was increased for up to 4 weeks after the event, particularly among the elderly, and was significantly associated with level of seismic activity. These disasters demonstrate how severe emotional stress may precipitate cardiac events in vulnerable and predisposed populations.

Air Pollution
Several studies have examined the impact of short-term air pollution exposures (most often fine particulate matter (PM$_{2.5}$), carbon monoxide, or oxides of nitrogen), and risk of OHCA. In studies based in metropolitan areas of Europe, United States, and Australia, elevated risks of OHCA have been temporally associated with increased levels of particulate matter. However, other studies from Washington State, United States, and Copenhagen, Denmark, did not find consistent associations. Long-term exposures to air pollution have been associated with increased mortality from CHD and exposure to roadway pollutants may elevate SCD risk.

SCD in the Patient Populations With Structural Heart Disease

Coronary Heart Disease
CHD underlies a significant proportion of SCD, especially in Western countries, and overt CHD is associated with marked increases in SCD risk. In the Framingham Study, pre-existing CHD was associated with 2.8- to 5.3-fold increases in SCD risk, and women and men have a 4- to 10-fold higher risk of SCD, respectively, after experiencing an MI. The absolute rate of SCD seems to be highest in the first 30 days after MI and decreases gradually with time, although the proportion of patients who die from non-SCD is greater in the first 18 months. The incidence of SCD after MI has declined in parallel with CHD mortality over time, with rates as low as 1%/y in patients receiving optimal medical therapy and revascularization. However, rates remain high in certain subsets of post-MI patients.

There are 3 general settings where SCD occurs in patients with CHD: (1) during or after acute MI, (2) provoked by coronary ischemia without MI, and (3) in the presence of myocardial structural alterations (fibrosis, scar, left ventricular dilatation) secondary to prior MI or chronic ischemia. Only 19% and 38% of cardiac arrest survivors develop a new Q-wave MI and enzymatic evidence of MI, respectively. The prevalence of acute coronary thrombus or active coronary lesion in autopsy series of SCD varies depending on autopsy protocol and histological techniques, ranging from 19% to 74%. With respect to the type of active lesion found at autopsy, approximately two-third of coronary thrombi are organizing, and late stage lesions or coronary erosions are more commonly encountered in women. In most series, stable plaques and chronic changes alone are found in ~50%
of SCD victims with CHD on autopsy. From these data, it seems that plaque rupture with or without associated thrombosis and MI is present in some, but not all, patients with CHD at the time of SCD.

The potential underlying mechanism precipitating SCD also differs depending on the setting in which it occurs and the chronicity of disease. The 2 most common mechanisms are thought to be polymorphic VT/VF precipitated by acute ischemia and infarction and monomorphic VT degenerating to VF arising from a reentrant circuit within or surrounding a myocardial scar. In addition to these primary arrhythmic causes, a significant proportion of SCDs in the post-MI population seem to be because of nonarrhythmic causes such as myocardial rupture and extensive reinfarction, and this percentage seems to be highest within the first month after MI.157 In patients with end-stage ischemic cardiomyopathy, other modes of death such as acute pump failure and respiratory arrest resulting in PEA, or primary bradyarrhythmias comprise a significant proportion of SCD as well.158

Risk Factors for SCD in Patients With Established CHD Left ventricular systolic dysfunction and severity of HF symptoms are currently the strongest predictors of SCD risk among patients with prior MI and ischemic cardiomyopathy.156–160 After MI, mortality risk increases gradually until the left ventricular ejection fraction (LVEF) declines to 40%, and then exponentially increases as LVEF decreases further.161 SCD rates reach 10% during a median follow-up of ≈2 years among patients with LVEF <30% and CHF in clinical trials.148,165 Based on randomized clinical trials performed in populations with low LVEFs and CHF,162–164 ICD therapy is recommended for patients with ischemic dilated cardiomyopathy, prior MI, New York Heart Association class II and III HF, and LVEF ≤35%.165 In contrast, ICD therapy does not reduce mortality in the early post-MI period (within 40 days),166,167 possibly because of a predominance of nonarrhythmic causes of death during this time window.157

Stratifying SCD risk based solely on LVEF and degree of systolic HF has 2 major well-recognized limitations. First, LVEF and New York Heart Association class are both strongly associated with other modes of cardiovascular death,148,165 and patients with the greatest functional impairment secondary to systolic HF and lowest LVEF are more likely to die from HF as opposed to SCD.158 The inability of these clinical markers to discriminate SCD risk from other competing causes of death has important clinical implications. In a recent prospective study series of 1100 patients with systolic dysfunction,169 patients with CHD who received primary prevention ICDs on the basis of LVEF and CHF were more likely to die than to experience an appropriate ICD therapy from their device. Second, the majority of patients who experience a SCA or SCD do not seem to have LV systolic dysfunction and clinical HF preceding death.7,19 In a prospective registry of cardiac arrests in the Netherlands, only 26% of SCAs with heart disease had HF before death, and only 19% of patients had an LVEF ≤30%.14 In a more contemporary cohort in Multnomah County, Oregon, one-third of SCAs who had an echocardiogram before death had an LVEF<35%.170

In addition to LVEF and CHF, other potential markers of increased SCD risk in patients with CHD include sustained VT induced at electrophysiology study, left ventricular scar size and heterogeneity on cardiac magnetic resonance, T-wave alternans, markers of autonomic function such as baroreflex sensitivity and impaired heart rate turbulence, and conventional ECG measures such as left bundle branch block, QRS duration, left ventricular hypertrophy, and QT interval.161,171–175 To date, only inducible sustained VT at electrophysiology study has been proven in a randomized clinical trial to identify individuals at a higher risk of SCA versus non-SCA.176 However, the sensitivity of this test in isolation is inadequate to guide ICD therapy, especially in patients with LVEF <30%,161,171 Recently, sustained VT at electrophysiology study was also found to be effective at stratifying arrhythmic death risk among patients with LVEF <35% in the early post-MI period.174

Risk Factors for SCD in Patients With Preserved LVEF Although the incidence of SCD is lower in patients with HF with preserved LVEF as compared with those with reduced LVEF, the ratio of SCD to progressive HF deaths is higher, with SCD comprising 11% to 28% of all deaths.175–177 Relatively little is known about SCD risk prediction in patients with CHD with preserved LVEFs. Prior history of MI, HF, and history of diabetes mellitus are consistent risk factors for SCD in this population.178,179 Other potential clinical risk factors identified in these populations include male sex, AF, physical inactivity, left bundle branch block on ECG, NT-proBNP (N-terminal pro-B type natriuretic peptide) levels, and severity of coronary artery disease.68,178,179

Cardiomyopathies Next to CHD, non–ischemic cardiomyopathies are the second most frequent cause of SCD in the United States and European countries, which account for ≈10% to 15% (Figure 2).7,10,18 Furthermore, the prevalence of cardiomyopathies in young autopsied SCD victims aged ≤35 years is higher and is reported to be 15% to 30%.7,14,25,180,181 However, non–ischemic cardiomyopathies are more frequently observed as a cause of SCD in Japan (≈30%–35% of SCD victims).182 The 3 major causally distinct cardiomyopathies are non–ischemic dilated cardiomyopathy (NIDCM), HCM, and ARVC.

Non–Ischemic Dilated Cardiomyopathy
NIDCM has an estimated prevalence of 1:2500183 and is defined by the presence of LV dilatation and LV systolic dysfunction in the absence of abnormal loading conditions (hypertension, valve disease) or coronary artery disease sufficient to cause global systolic impairment.184 Causes of NIDCM include gene mutations, myocarditis caused by viral, bacterial, fungal, or parasitic infections, toxicity because of alcohol, chemotherapeutic agents, metals, and autoimmune and systemic disorders. However, the majority of cases remain unexplained despite a thorough evaluation. Inherited NIDCM is reported to occur in ≤40% of cases, mostly in an autosomal dominant fashion.185 To date, mutations in >40 genes have been reported, in which TTN, MYH7, TNNT2, and LMNA are the most frequently identified, encoding titin, myosin heavy chain, cardiac troponin T (all in sarcomere), and lamin A/C (in nuclear envelope), respectively.185

Prior episodes of sustained VT, history of syncope, reduced LVEF, HF, and family history of SCD are the primary
risk factors used to identify patients at a sufficiently high enough SCD risk to warrant ICD therapy. Two primary prevention randomized trials of ICD therapy included NIDCM patients with LVEF of ≤35% and HF symptoms (New York Heart Association I–III) and demonstrated significant reductions in the SCD rate in patients with NIDCM (hazard ratio of 0.20188 and 0.34199) and reductions in total mortality when combined in meta-analysis. However, as in patients with ischemic cardiomyopathy, LVEF has a low sensitivity and specificity for predicting SCD and more specific markers are needed. Recently, midwall fibrosis detected by late gadolinium enhancement cardiac magnetic resonance was demonstrated to improve SCD risk prediction beyond LVEF in a large study of patients with NIDCM.

Hypertrophic Cardiomyopathy

HCM, defined by increased LV wall thickness not solely explained by abnormal loading conditions, is considered the most common inherited cardiac disease with an estimated prevalence of 1:500 in the general population. In adult patients, the clinical diagnosis of HCM is made by cardiac imaging showing a left ventricular wall thickness of ≥15 mm in ≥1 segments. HCM can be present with lesser degrees of the wall thickening (13–14 mm), but other features of HCM, such as a family history, noncardiac symptoms and signs, ECG abnormalities, and abnormalities on multimodality cardiac imaging, are required to support the diagnosis. To date, >1500 mutations in >11 genes encoding components of the sarcomere or desmosomes (plakophilin 2, desmoglein 2, and desmoplakin) have been identified, with the most common encoding β-myosin heavy chain and myosin binding protein C.

The annual incidence of cardiovascular death in HCM is 0.5% to 2% in contemporary series, and SCD from a lethal ventricular arrhythmia remains one of the common modes of death. SCD is more likely to occur in young patients (<30 years) and is uncommon in older patients (>60 years). Established risk factors for SCD in patients with HCM include a history of unexplained syncope, family history of SCD, a maximal left ventricular wall thickness of ≥30 mm, repetitive non–sustained VT, and abnormal blood pressure response to exercise. According to the American College of Cardiology Foundation and American Heart Association guidelines, the presence of ≥1 of these risk factors can be used to select patients for primary prevention ICD placement. The most recent European Society of Cardiology guidelines recommend the use of a prediction model, which incorporates absolute risk and individual effect sizes of the above and other SCD risk factors (Figure 5) at 1- to 2-year intervals. Implantation of an ICD is recommended in patients with an estimated 5-year SCD risk of ≥6% and a life expectancy of >1 year (class IIa).

Arrhythmogenic Right Ventricular Cardiomyopathy

ARVC is a genetically determined heart muscle disorder characterized by fibrofatty replacement of the right ventricular myocardium. As the disease progresses, the left ventricle may also become involved. The estimated prevalence of ARVC is 1: 2000 to 5000, and ≤60% of the patients have a mutation with an autosomal dominant trait and incomplete penetrance. Among ≥15 genes have been reported to cause ARVC, mutations in genes encoding components of cardiac desmosomes (plakophilin 2, desmoglein 2, and desmoplakin) are most frequently identified. The 2010 Task Force diagnostic criteria for ARVC consist of major and minor findings in 6 different categories: (1) structural alterations, (2) tissue characterization, (3) repolarization abnormalities, (4) depolarization abnormalities, (5) arrhythmias, and (6) family history including genetic testing.

SCD is a common cause of death in patients with ARVC especially in those in the fourth decade of life or younger, and it may be the first arrhythmic event in up to 50% of cases. Several observational studies showed that the annual rate of death or VF in patients treated by ICDs was 1.5% to 4%, and predictors of appropriate ICD therapy include a history of a cardiac arrest or VT with hemodynamic compromise, younger age, LV involvement, unexplained syncope, presence of non–sustained VT, and inducibility during electrophysiology study. Current American College of Cardiology Foundation/ American Heart Association/Heart Rhythm Society guidelines recommend the prophylactic use of an ICD in those who have ≥1 risk factors for SCD (class IIa).

Valvular Heart Disease

Valvular heart disease is reported to be the cause of death in 1% to 5% of the SCD victims (Figure 2). Even after surgical procedures, SCD occurs in 15% to 30% of patients, accounting for 0.2% to 0.9%/y and is most commonly triggered by ventricular arrhythmias. Patients with aortic stenosis are at the highest risk of SCD after valve replacement, particularly within 2 years. Before valve replacement, asymptomatic patients with severe AS have annual SCD rates of 1%–3% and recent observational data suggest that this risk may be lowered by early surgery. The role of mitral valve prolapse in SCD is controversial. The majority of mitral valve prolapse is thought to be benign, but there are certain characteristics such as leaflet thickness, redundancy, and increased LV diameter that seem to be associated with higher risk, and recent data suggest that women with bileaflet prolapse and complex...
ventricular ectopy may be at particular risk.\textsuperscript{211} Overall, data on SCD risk stratification and appropriate use of ICDs in patients with valvular disease are scarce and further studies in this at-risk subgroup of patients are needed.

SCD in the Absence of Structural Heart Disease

Autopsy-Negative SCD/Sudden Unexplained Death

Autopsy-negative sudden death is more commonly reported in younger individuals. Autopsy series from Ireland\textsuperscript{24} and Sydney\textsuperscript{181} reported that 27\% to 29\% of sudden arrhythmic deaths in individuals aged <35 years had no demonstrable structural heart disease on autopsy. In a Danish nationwide study of SCD,\textsuperscript{23} this proportion was even higher (43\%). However, when detailed histologic examinations are performed, the percentage of autopsy-negative SCD is much lower. In a prospective study of 273 consecutive SCD cases aged 1 to 35 years in Italy,\textsuperscript{180} detailed histologic examination identified concealed pathologic substrates, such as focal myocarditis, regional ARVC, and conduction system abnormalities in 60 of 76 cases without macroscopic evidence for structural heart disease. After histologic exam, only 16 (6\%) had no detectable abnormalities. Although discorces in the frequency of the autopsy-negative SCDs could be because of differences in regional genetic background, it is likely that the frequency of autopsy-negative cases would decrease if more detailed histologic examinations were carried out in all SCD victims.

Among patients with autopsy negative SCD, \textasciitilde 50\% will have inherited arrhythmic syndromes,\textsuperscript{212,213} such as, long-QT syndrome (LQTS), BrS, catecholaminergic polymorphic VT, and early repolarization syndrome. Even when structural abnormalities of uncertain significance are found, inherited arrhythmic syndromes seem to underlie a significant fraction of SCDs.\textsuperscript{214} Taken together, these findings suggest that substantial numbers of SCD may be attributable to inherited arrhythmic syndromes in the young. Performing molecular autopsies in cases with autopsy-negative SCD and cascade screening of families is important to establish the cause of death and to identify relatives potentially at high SCD risk. In cases of sudden unexplained death, where a diagnosis is not made either by antemortem or postmortem analysis, genetic testing of family members reveals a possible disease-causing mutation in 31\% of families, and inherited arrhythmic syndromes comprise 30\% of these mutations.\textsuperscript{215}

Inherited Arrhythmic Disorders and Their Epidemiology

Long-QT Syndrome

Congenital LQTS is a hereditary disorder, characterized by delayed myocardial repolarization resulting in prolongation of the QT interval on 12-lead ECG and predisposition to torsade de points, which can result in SCD.\textsuperscript{216,217} Approximately 75\% of patients with LQTS and 95\% of genotype-positive LQTS will have a mutation in genes encoding the slow component (\textit{KCNJ1}, LQT1) and the rapid component (\textit{KCNH2}, LQT2) of the delayed rectifier potassium current and the cardiac sodium channel (\textit{SCN5A}, LQT3).\textsuperscript{218,219} Conversely, it is estimated that 25\% to 35\% of genetically affected patients have a normal or borderline QTc at rest,\textsuperscript{219,220} requiring exercise or a catecholamine infusion to disclose the masked QT interval.\textsuperscript{217,220,221} To directly estimate the prevalence of LQTS, Schwartz et al\textsuperscript{222} performed 12-lead ECGs in 43,080 white infants. Prolonged QTc intervals of 451 to 460, 461 to 470, and \textasciitilde 470 ms were observed in 177 (0.41\%), 28 (0.06\%), and 31 (0.07\%) infants, respectively. Of these, 17 of 43,080 infants were found to be affected by LQTS on the basis of genetic testing and further clinical evaluation, indicating a prevalence among whites of 1:2,534. Extrapolating these results to the nongenotyped infants, the authors estimated the prevalence of LQTS was closer to 1:2,000.\textsuperscript{222}

The estimated incidence of cardiac arrest or SCD before the age of 40 years in untreated patients is estimated to be 0.30%/y, 0.60%/y, and 0.56%/y in LQT1, LQT2, and LQT3, respectively.\textsuperscript{216} Most arrhythmic events developed during exercise or emotional stress in LQT1, at rest or with sudden noises in LQT2, and at rest or during sleep in LQT3.\textsuperscript{223} Other risk factors for arrhythmic events in LQTS include prior history of syncope, significant QTc prolongation,\textsuperscript{219,224} and location and number of mutations.\textsuperscript{219,225-227} \(\beta\)-Blockers remain the mainstay of therapy for the majority of these patients, and ICDs are generally reserved for patients who have experienced a cardiac arrest.\textsuperscript{228}

Brugada Syndrome

BrS was first described in 1992\textsuperscript{229} and is thought to underlie, to a certain extent, the mystery of unexpected nocturnal death, which is colloquially called Pokkuri in Japan, Lai Tai in Thailand, and Bangungut in the Philippines.\textsuperscript{230} BrS is a primary electrical disorder affecting middle-aged men with their first arrhythmic event typically developing during sleep at a mean age of 40 years.\textsuperscript{231} The clinical phenotype is 8 to 10\% more prevalent in men than in women, which is attributable, at least in part, to the higher testosterone level in men.\textsuperscript{232} Twelve-lead ECGs at rest are characterized by a coved type ST-segment and J point elevation of \(\textgeq 2\) mm (0.2 mV) followed by a negative T wave in the right precordial leads (V1-3), which is referred to as a type 1 Brugada ECG.\textsuperscript{231}

In the 2013 Heart Rhythm Society/Asian Pacific Heart Rhythm Association expert consensus statement,\textsuperscript{228} BrS is diagnosed when a type 1 ST-segment elevation is observed either spontaneously or after the administration of a sodium channel blocking agent in at least 1 right precordial lead (V1 and V2), which is placed in a standard or a superior position; in which case, documentation of VT/VF, clinical symptoms, or a family history is no longer necessary. Table 1 displays the reported prevalence of a type 1 Brugada ECG across population-based studies. The prevalence of the type 1 ECG pattern in adults is greatest in Japan,\textsuperscript{233,234} the Philippines,\textsuperscript{235} and among Japanese-Americans in North America\textsuperscript{236} (0.15\%–0.27\% [1:350–700]). Rates in Europe\textsuperscript{237-239} (0\%–0.017\% [1:550–600]) and North America\textsuperscript{240,241} (0.005\%–0.1\% [1:1000–2000]) seem to be lower. These estimates of BrS do not account for temporal variability of the ECG morphology\textsuperscript{228} or patients who exhibit type 1 ECG only in the superior lead positions or after drug-provocation.\textsuperscript{228}
The primary risk factors for SCD in type 1 BrS are prior history of syncope or aborted SCD. In recently published multicenter registry studies, the incidence of the cardiac events (SCD, VF, and appropriate ICD shocks) in type I BrS ranged from 7.7% to 10.2%/y, 0.6%–3.0%/y, and 0.5%–0.8%/y in those with a history of aborted SCD because of VF, syncopeal episodes, and no symptoms, respectively.

**Catecholaminergic Polymorphic VT**

Catecholaminergic polymorphic VT is a familial arrhythmogenic disorder characterized by polymorphic ventricular tachyarrhythmias or bidirectional VT induced by physical or emotional stress. The patients show no detectable cardiac morphological abnormalities, and the ECG is normal except for a lower heart rate at rest. Affected patients usually develop arrhythmic events (syncope, aborted cardiac arrest, or SCD) during adrenergic activity in the first or second decade of life, and the clinical course is considered to be highly malignant. Without proper treatment such as β-blockers, flecainide, and ICDs, mortality reaches >30% by the age of 30 years and the estimated 8-year fatal or aborted SCA event rate after the diagnosis is 13%. The population prevalence of catecholaminergic polymorphic VT is difficult to estimate because it cannot be detected on resting 12-lead ECG, but is projected to be ≈1:10,000.

**Early Repolarization Syndrome**

An early repolarization ECG pattern (ERP), which consists of a J wave elevation ≥0.1 mV, either notched or slurred, accompanied by an ST-segment elevation, has long been considered to be a benign finding and unrelated to serious cardiac events. This notion has recently been challenged by studies demonstrating that an ERP in the inferior and lateral leads is more commonly found in patients with idiopathic VF as compared with controls, raising the possibility that the ERP may be a marker of an arrhythmogenic substrate. Considering these data, a recent expert consensus panel defined ERP as the presence of J point elevation ≥0.1 mV in ≥2 contiguous inferior and lateral leads, and early repolarization syndrome is diagnosed in the presence of VF or polymorphic VT or autopsy negative SCD victim with a previous ECG demonstrating ERP.

The question of whether an ERP on resting ECG confers an increased risk of SCD in the general population has been examined in several population-based studies, which are summarized in Table 2. The definition of ERP varies widely between these studies. In some studies, ERP had to be present in the inferior and lateral leads, and others considered J point ST elevations in all body surface leads to be ERP. Prevalence estimates in these studies range from 1% to 24% and 0.6% to 6.4% for J point elevation of ≥0.1 and 0.2 mV, respectively. Notwithstanding these differences in methodology, ERP is reported to be more prevalent in younger age groups, men, or individuals of African descent. The majority of European studies and Japanese studies...

---

**Table 1. Prevalence of a Type 1 Brugada ECG* in the Population Studies**

<table>
<thead>
<tr>
<th>Country</th>
<th>Authors</th>
<th>Year Published</th>
<th>Individuals Screened, n</th>
<th>Male Sex, %</th>
<th>Mean Age or Range of Age, y</th>
<th>Type 1 ECG, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>Junttila et al264</td>
<td>2004</td>
<td>2479</td>
<td>100</td>
<td>18–30</td>
<td>0</td>
</tr>
<tr>
<td>Greece</td>
<td>Letsas et al237</td>
<td>2007</td>
<td>11 488</td>
<td>58</td>
<td>15–98</td>
<td>2 (0.017)</td>
</tr>
<tr>
<td>Italy</td>
<td>Gallagher et al238</td>
<td>2008</td>
<td>12 012</td>
<td>91</td>
<td>30±9</td>
<td>2 (0.017)</td>
</tr>
<tr>
<td>Germany</td>
<td>Sinner et al239</td>
<td>2009</td>
<td>4 149</td>
<td>49</td>
<td>51±14</td>
<td>0</td>
</tr>
<tr>
<td>Denmark</td>
<td>Pecini et al240</td>
<td>2010</td>
<td>18 974</td>
<td>45†</td>
<td>52±12†</td>
<td>0</td>
</tr>
<tr>
<td>North America</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>Lee et al241</td>
<td>2005</td>
<td>3 983</td>
<td>100</td>
<td>31</td>
<td>4 (0.100)</td>
</tr>
<tr>
<td>United States (Japanese–American)</td>
<td>Ilbo et al242</td>
<td>2006</td>
<td>8 006</td>
<td>100</td>
<td>45–68</td>
<td>12 (0.150)</td>
</tr>
<tr>
<td>United States</td>
<td>Patel et al243</td>
<td>2009</td>
<td>162 590</td>
<td>65</td>
<td>Not described</td>
<td>8 (0.005)</td>
</tr>
<tr>
<td>Asia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>Sakabe et al244</td>
<td>2003</td>
<td>3 339</td>
<td>79</td>
<td>&gt;18</td>
<td>5 (0.150)†</td>
</tr>
<tr>
<td>Japan</td>
<td>Yamakawa et al245</td>
<td>2004</td>
<td>20 387</td>
<td>51</td>
<td>10</td>
<td>1 (0.005)</td>
</tr>
<tr>
<td>Japan</td>
<td>Oe et al246</td>
<td>2005</td>
<td>21 944</td>
<td>51</td>
<td>7</td>
<td>1 (0.005)</td>
</tr>
<tr>
<td>Japan</td>
<td>Tsui et al247</td>
<td>2008</td>
<td>13 904</td>
<td>27</td>
<td>58±10</td>
<td>37 (0.266)</td>
</tr>
<tr>
<td>Philippines</td>
<td>Gervacio-Domingo et al248</td>
<td>2008</td>
<td>3 907</td>
<td>Not described</td>
<td>≥20</td>
<td>7 (0.179)</td>
</tr>
<tr>
<td>Taiwan</td>
<td>Juang et al</td>
<td>2011</td>
<td>20 562</td>
<td>39</td>
<td>49±21</td>
<td>1 (0.005)</td>
</tr>
<tr>
<td>Korea</td>
<td>Uhn et al</td>
<td>2011</td>
<td>10 867</td>
<td>100</td>
<td>21±5</td>
<td>0</td>
</tr>
</tbody>
</table>

*Studies including patients with a coved type ECG and J point amplitude ≥0.1 mV were excluded.
†In the first examination.
‡Those with a continuous type 1 ECG.
found significant associations between the ERP and cardiac or sudden arrhythmic death, whereas studies conducted in the United States generally did not.253,258,259 One US study suggested that the association between ERP and SCD may be limited to women and white individuals.258 These results suggest that there may be an ethnic, racial, and sex differences in the relationship between the ERP and SCD. It is important to note that the calculated relative risks for sudden arrhythmic death associated with a J point elevation of 0.1 mV are modest (Table 2) and the absolute risk of arrhythmic death in asymptomatic individuals with the ERP on ECG is extremely low.255 Three-fold elevations in sudden/arrhythmic death have been observed when ERP is more strictly defined as a J point elevation of >0.2 mV associated with horizontal/descending ST segment limited to the inferior leads.256,263 However, this pattern was only noted in 0.3% of the population.263

<table>
<thead>
<tr>
<th>Country</th>
<th>Authors</th>
<th>Year Published</th>
<th>Position of ERP</th>
<th>Individuals Screened, n</th>
<th>Male, Sex, %</th>
<th>Mean Age at Baseline, y</th>
<th>J Point Elevation, n (%)</th>
<th>RR of Death According to the ERP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>Tikkanen et al256</td>
<td>2009</td>
<td>Inf or lat</td>
<td>10 864</td>
<td>52</td>
<td>44±8</td>
<td>630 (5.8)</td>
<td>1.28* in inf 1.43* in lat 1.43* in lat 0.75 in lat</td>
</tr>
<tr>
<td>Germany</td>
<td>Sinner et al257</td>
<td>2010</td>
<td>Inf or lat</td>
<td>6213</td>
<td>49</td>
<td>52±10</td>
<td>812 (13.1)</td>
<td>Not described</td>
</tr>
<tr>
<td>France</td>
<td>Rollin et al258</td>
<td>2012</td>
<td>Inf or lat</td>
<td>1161</td>
<td>52</td>
<td>50±9</td>
<td>159 (13.7)</td>
<td>Not described</td>
</tr>
<tr>
<td>North America</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United States</td>
<td>Klatsky et al253</td>
<td>2003</td>
<td>All</td>
<td>73 088</td>
<td>44</td>
<td>37±13</td>
<td>670 (0.9)</td>
<td>1.73 in inf 0.83 in lat</td>
</tr>
<tr>
<td>United States</td>
<td>Uberoi et al259</td>
<td>2011</td>
<td>Inf or lat</td>
<td>29 281</td>
<td>87</td>
<td>55±15</td>
<td>664 (2.3)</td>
<td>8±4</td>
</tr>
<tr>
<td>United States</td>
<td>Olson et al258</td>
<td>2011</td>
<td>All</td>
<td>15 141</td>
<td>44</td>
<td>54±6</td>
<td>1866 (12.3)</td>
<td>Not described</td>
</tr>
<tr>
<td>United States</td>
<td>Iikhanoff et al259</td>
<td>2014</td>
<td>All</td>
<td>5039</td>
<td>46</td>
<td>25</td>
<td>1249 (20.9)†</td>
<td>Not described</td>
</tr>
<tr>
<td>Asia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>Haruta et al260</td>
<td>2011</td>
<td>Inf or lat</td>
<td>5976</td>
<td>44</td>
<td>Not described</td>
<td>1429 (23.9)†</td>
<td>24±15</td>
</tr>
<tr>
<td>Japan</td>
<td>Hisamatsu et al261</td>
<td>2013</td>
<td>All§</td>
<td>7630</td>
<td>41</td>
<td>52</td>
<td>264 (3.5)</td>
<td>0.75* 1.83*</td>
</tr>
</tbody>
</table>

ERP indicates early repolarization pattern; Inf, inferior leads; Lat, lateral leads; and RR, relative risk.
*Statistically significant.
†For the cardiovascular death.
‡At baseline.
§≥0.2 mV in anterior leads.

Conclusions
SCD is a major public health problem all over the world, and although resuscitation rates are improving, the majority of individuals who experience SCA will not survive, and often the underlying cardiac condition is not recognized before death. Behind these tragic events, there are various causes, risks, and predisposing conditions, which differ in the prevalence according to region, age, ethnicity, race, and sex. As such, a multifaceted approach, which addresses risk factors both in high- and low-risk populations, will be required to decrease the burden of SCD. Population-wide approaches as well as improved identification of high-risk individuals who will benefit from ICDs will be crucial to prevent SCD events and improve patient outcomes. Although substantial progress has been made in this field, further studies addressing SCD prevention across the whole spectrum of disorders, from CHD in the general population to the rarer inherited disorders, are warranted to address many remaining uncertainties on the multitude of factors, which underlie susceptibility to SCD.

Sources of Funding
Dr Shimizu was supported in part by Grants from the Ministry of Health, Labor and Welfare of Japan for Clinical Research on Intractable Diseases (H24-033, H26-040) and a Nippon Medical School Grant-in-Aid for Medical Research. Dr Albert is supported by grants received from the St. Jude Medical and the National Heart, Lung, and Blood Institute (HL091069, HL11690) and an Established Investigator Award from the American Heart Association.

Disclosures
None.
References


116. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primar-


117. Lemaitre RN, Siscovick DS, Raghunathan TE, Weinmann S, Aragbut-


118. Multiple Risk Factor Intervention Trial Research Group. Risk factor


120. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vig-


126. Davidson M. Risk of cardiovascular disease and sudden death in schizo-


127. Weeke P, Jensen A, Folke F, et al. Antidepressant use and risk of out-


135. Elmore KB, Raun LH, Persse D. A case-crossover analysis of out-of-


146. Adelson L, Hoffman W. Sudden death from coronary disease relat-


Hohnloser SH, K


Shimizu W, Noda T, Takaki H, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital


The Spectrum of Epidemiology Underlying Sudden Cardiac Death
Meiso Hayashi, Wataru Shimizu and Christine M. Albert

doi: 10.1161/CIRCRESAHA.116.304521

_Circulation Research_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/116/12/1887

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation Research_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation Research_ is online at:
http://circres.ahajournals.org//subscriptions/